Promedior Orphan Status 2014
September 2, 2014
Promedior, Inc. has been granted orphan drug designation for PRM-151 for the treatment of myelofibrosis by the U.S. Food and Drug Administration (FDA). Click here to read more.
September 2, 2014
Promedior, Inc. has been granted orphan drug designation for PRM-151 for the treatment of myelofibrosis by the U.S. Food and Drug Administration (FDA). Click here to read more.